Risankizumab

Risankizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	interleukin 23A
Clinical data
Pronunciation	/ˌrɪsənˈkɪzʊmæb/; RIS-ən-KIZ-uu-mab
Trade names	Skyrizi
Other names	BI-655066, ABBV-066, risankizumab-rzaa
AHFS/Drugs.com	Monograph
MedlinePlus	a619035
License data	US DailyMed: Risankizumab;
Pregnancy; category	AU: B1;
Routes of; administration	Subcutaneous injection
ATC code	L04AC18 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; Rx-only;
Identifiers
CAS Number	1612838-76-2;
PubChem SID	363669765;
IUPHAR/BPS	8922;
DrugBank	DB14762;
ChemSpider	none;
UNII	90ZX3Q3FR7;
KEGG	D11052;
ChEMBL	ChEMBL3990029;
Chemical and physical data
Formula	C6476H9992N1720O2016S44
Molar mass	145611.84 g·mol−1

Risankizumab, sold under the brand name Skyrizi (/skaɪˈrɪzi/ sky-RIZZ-ee), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.

The most common side effects include upper respiratory infections (nose and throat infection).

Risankizumab is approved for medical use in the European Union, the United States, Canada, and Japan.